vs
Side-by-side financial comparison of STRATA Skin Sciences, Inc. (SSKN) and Velo3D, Inc. (VELO). Click either name above to swap in a different company.
Velo3D, Inc. is the larger business by last-quarter revenue ($9.4M vs $9.3M, roughly 1.0× STRATA Skin Sciences, Inc.). STRATA Skin Sciences, Inc. runs the higher net margin — 0.6% vs -231.9%, a 232.6% gap on every dollar of revenue. On growth, STRATA Skin Sciences, Inc. posted the faster year-over-year revenue change (-3.0% vs -25.2%). STRATA Skin Sciences, Inc. produced more free cash flow last quarter ($-551.0K vs $-8.3M). Over the past eight quarters, STRATA Skin Sciences, Inc.'s revenue compounded faster (17.3% CAGR vs -1.8%).
Strata Skin Sciences is an American medical device company focused on the design, development and commercialization of non-invasive tools to provide additional information to dermatologists during melanoma skin examinations.
Velo3D, Inc. develops and sells advanced end-to-end metal additive manufacturing (3D printing) solutions, comprising industrial-grade printers, specialized processing software, and high-performance metal materials. It primarily serves global aerospace, defense, energy, semiconductor and industrial manufacturing markets, enabling customers to produce complex, high-precision metal parts that are difficult to manufacture with traditional methods.
SSKN vs VELO — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $9.3M | $9.4M |
| Net Profit | $58.0K | $-21.9M |
| Gross Margin | 61.8% | -73.6% |
| Operating Margin | 5.3% | -231.0% |
| Net Margin | 0.6% | -231.9% |
| Revenue YoY | -3.0% | -25.2% |
| Net Profit YoY | 101.3% | -2.9% |
| EPS (diluted) | $0.14 | $-0.87 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $9.3M | $9.4M | ||
| Q3 25 | $6.9M | $13.6M | ||
| Q2 25 | $7.7M | $13.6M | ||
| Q1 25 | $6.8M | $9.3M | ||
| Q4 24 | $9.6M | $12.6M | ||
| Q3 24 | $8.8M | $8.2M | ||
| Q2 24 | $8.4M | $10.3M | ||
| Q1 24 | $6.8M | $9.8M |
| Q4 25 | $58.0K | $-21.9M | ||
| Q3 25 | $-1.6M | $-11.2M | ||
| Q2 25 | $-2.6M | $-13.3M | ||
| Q1 25 | $-2.1M | $-25.0M | ||
| Q4 24 | $-4.6M | $-21.3M | ||
| Q3 24 | $-2.1M | $-21.9M | ||
| Q2 24 | $-91.0K | $935.0K | ||
| Q1 24 | $-3.4M | $-27.5M |
| Q4 25 | 61.8% | -73.6% | ||
| Q3 25 | 60.4% | 3.2% | ||
| Q2 25 | 56.2% | -11.7% | ||
| Q1 25 | 53.5% | 7.5% | ||
| Q4 24 | 61.4% | -3.5% | ||
| Q3 24 | 60.1% | 49.4% | ||
| Q2 24 | 59.0% | -28.0% | ||
| Q1 24 | 45.6% | -28.8% |
| Q4 25 | 5.3% | -231.0% | ||
| Q3 25 | -16.9% | -73.3% | ||
| Q2 25 | -30.1% | -85.4% | ||
| Q1 25 | -25.0% | -123.6% | ||
| Q4 24 | -44.7% | -167.0% | ||
| Q3 24 | -18.2% | -213.8% | ||
| Q2 24 | -5.7% | -187.7% | ||
| Q1 24 | -42.7% | -211.1% |
| Q4 25 | 0.6% | -231.9% | ||
| Q3 25 | -23.4% | -82.0% | ||
| Q2 25 | -33.6% | -97.7% | ||
| Q1 25 | -31.2% | -268.4% | ||
| Q4 24 | -47.6% | -168.5% | ||
| Q3 24 | -23.6% | -265.3% | ||
| Q2 24 | -1.1% | 9.0% | ||
| Q1 24 | -49.8% | -281.2% |
| Q4 25 | $0.14 | $-0.87 | ||
| Q3 25 | $-0.36 | $-0.65 | ||
| Q2 25 | $-0.62 | $-0.94 | ||
| Q1 25 | $-0.51 | $-1.87 | ||
| Q4 24 | $-2.01 | $7.06 | ||
| Q3 24 | $-0.51 | $-35.52 | ||
| Q2 24 | $-0.03 | $1.65 | ||
| Q1 24 | $-0.10 | $-55.51 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $7.9M | $39.0M |
| Total DebtLower is stronger | $15.3M | $31.0M |
| Stockholders' EquityBook value | $2.9M | $38.2M |
| Total Assets | $30.5M | $105.3M |
| Debt / EquityLower = less leverage | 5.28× | 0.81× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $7.9M | $39.0M | ||
| Q3 25 | $7.1M | $11.8M | ||
| Q2 25 | $6.0M | $854.0K | ||
| Q1 25 | $6.5M | $3.9M | ||
| Q4 24 | $7.3M | $1.2M | ||
| Q3 24 | $7.1M | $1.6M | ||
| Q2 24 | $5.5M | $3.2M | ||
| Q1 24 | $5.2M | $10.9M |
| Q4 25 | $15.3M | $31.0M | ||
| Q3 25 | $15.3M | $23.0M | ||
| Q2 25 | $15.0M | $22.5M | ||
| Q1 25 | $15.0M | $21.7M | ||
| Q4 24 | $15.0M | $5.7M | ||
| Q3 24 | $15.0M | $32.3M | ||
| Q2 24 | $15.0M | $33.5M | ||
| Q1 24 | $15.0M | $44.0M |
| Q4 25 | $2.9M | $38.2M | ||
| Q3 25 | $1.3M | $29.9M | ||
| Q2 25 | $532.0K | $21.4M | ||
| Q1 25 | $3.0M | $32.8M | ||
| Q4 24 | $5.0M | $39.7M | ||
| Q3 24 | $9.4M | $34.4M | ||
| Q2 24 | $9.5M | $52.1M | ||
| Q1 24 | $9.4M | $45.5M |
| Q4 25 | $30.5M | $105.3M | ||
| Q3 25 | $30.7M | $93.7M | ||
| Q2 25 | $29.5M | $78.4M | ||
| Q1 25 | $33.0M | $91.3M | ||
| Q4 24 | $34.9M | $89.2M | ||
| Q3 24 | $39.4M | $110.8M | ||
| Q2 24 | $38.8M | $116.7M | ||
| Q1 24 | $39.2M | $136.1M |
| Q4 25 | 5.28× | 0.81× | ||
| Q3 25 | 11.65× | 0.77× | ||
| Q2 25 | 28.20× | 1.05× | ||
| Q1 25 | 5.04× | 0.66× | ||
| Q4 24 | 3.02× | 0.14× | ||
| Q3 24 | 1.60× | 0.94× | ||
| Q2 24 | 1.58× | 0.64× | ||
| Q1 24 | 1.59× | 0.97× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-239.0K | $-7.7M |
| Free Cash FlowOCF − Capex | $-551.0K | $-8.3M |
| FCF MarginFCF / Revenue | -5.9% | -88.3% |
| Capex IntensityCapex / Revenue | 3.4% | 6.4% |
| Cash ConversionOCF / Net Profit | -4.12× | — |
| TTM Free Cash FlowTrailing 4 quarters | $-4.4M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-239.0K | $-7.7M | ||
| Q3 25 | $-64.0K | $-6.0M | ||
| Q2 25 | $-1.9M | $-1.2M | ||
| Q1 25 | $-550.0K | $-12.3M | ||
| Q4 24 | $703.0K | $-2.2M | ||
| Q3 24 | $-302.0K | $-2.0M | ||
| Q2 24 | $591.0K | $-8.0M | ||
| Q1 24 | $-804.0K | $-20.5M |
| Q4 25 | $-551.0K | $-8.3M | ||
| Q3 25 | $-1.1M | $-6.3M | ||
| Q2 25 | $-2.0M | $-3.0M | ||
| Q1 25 | $-749.0K | — | ||
| Q4 24 | $199.0K | $-2.2M | ||
| Q3 24 | $-364.0K | $-2.0M | ||
| Q2 24 | $246.0K | $-8.0M | ||
| Q1 24 | $-1.5M | $-20.5M |
| Q4 25 | -5.9% | -88.3% | ||
| Q3 25 | -15.6% | -46.5% | ||
| Q2 25 | -26.1% | -22.2% | ||
| Q1 25 | -11.0% | — | ||
| Q4 24 | 2.1% | -17.7% | ||
| Q3 24 | -4.1% | -24.2% | ||
| Q2 24 | 2.9% | -77.1% | ||
| Q1 24 | -22.6% | -209.8% |
| Q4 25 | 3.4% | 6.4% | ||
| Q3 25 | 14.7% | 2.3% | ||
| Q2 25 | 0.8% | 13.3% | ||
| Q1 25 | 2.9% | 0.0% | ||
| Q4 24 | 5.3% | 0.2% | ||
| Q3 24 | 0.7% | 0.2% | ||
| Q2 24 | 4.1% | 0.0% | ||
| Q1 24 | 10.7% | 0.1% |
| Q4 25 | -4.12× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -8.52× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
SSKN
| Dermatology Recurring Procedures | $6.1M | 65% |
| Dermatology Procedures Equipment | $3.2M | 35% |
VELO
Segment breakdown not available.
